Go Deep
Cogent Biosciences, Inc.
Cogent Biosciences, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 15,756 | -12.5 | 9.16 | 0.46 | 2,675.11 |
| Oct 2026 | 15,739 | -13.0 | 9.18 | 0.46 | 2,672.77 |
| Oct 2026 | 15,361 | -13.7 | 9.62 | 0.46 | 2,802.30 |
| Oct 2026 | 15,358 | -13.7 | 9.62 | 0.46 | 2,795.99 |
| Oct 2026 | 15,222 | -13.9 | 9.78 | 0.46 | 2,845.44 |
| Oct 2026 | 14,881 | -14.5 | 10.18 | 0.46 | 2,962.06 |
| Oct 2026 | 14,828 | -14.6 | 10.24 | 0.46 | 2,972.72 |
| Oct 2026 | 14,861 | -14.5 | 10.21 | 0.46 | 2,955.38 |
Cogent Biosciences, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -96,405,000.0 | -97,352,000.0 | -102,492,000.0 | -80,930,000.0 |
| EPS | -0.5 | -0.5 | -0.6 | -0.6 |
Cogent Biosciences, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Profit | -328,937,000.0 | -255,859,000.0 | -192,410,000.0 | -140,241,000.0 | — |
| EPS | -2.0 | -2.3 | -2.4 | -2.4 | — |
Cogent Biosciences, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 937,607,000.0 | 327,898,000.0 | 313,437,000.0 | 300,810,000.0 | — |
| Total Liabilities | 301,236,000.0 | 71,612,000.0 | 55,635,000.0 | 45,075,000.0 | — |
| Total Equity | 636,371,000.0 | 256,286,000.0 | 257,802,000.0 | 255,735,000.0 | — |
Owes vs Owns
Cogent Biosciences, Inc. owed $0.36 for every $1 it owned in Jun 2026, up from $0.15 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.36× | 0.32× | 0.22× | 0.18× | 0.15× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Cogent Biosciences, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 96.1%Fixed assets (tangible) 2.5%Other assets 1.4%
How it's funded — Dec 2025
Long-term debt 23.8%Payables 1.0%Other liabilities 7.2%Shareholders' equity 67.9%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 900.8 | 287.1 | 265.7 | 259.3 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 23.5 | 26.6 | 30.3 | 31.1 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 7.5 | 0.0 |
| Other assets | 13.3 | 14.3 | 9.9 | 10.4 |
| Liabilities & equity | ||||
| Short-term debt | 1.5 | 1.6 | 1.4 | 1.4 |
| Long-term debt | 222.9 | 15.9 | 17.5 | 18.2 |
| Payables | 9.5 | 12.0 | 10.7 | 5.8 |
| Other liabilities | 67.3 | 42.1 | 26.1 | 19.6 |
| Shareholders' equity | 636.4 | 256.3 | 257.8 | 255.7 |
| Net tangible assets | 636.4 | 256.3 | 257.8 | 255.7 |
Cogent Biosciences, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -264,444,000.0 | -207,791,000.0 | -153,624,000.0 | -118,638,000.0 | — |
| Investing Activities | -399,526,000.0 | 38,276,000.0 | -97,824,000.0 | -124,718,000.0 | — |
| Financing Activities | 878,233,000.0 | 214,451,000.0 | 163,536,000.0 | 163,558,000.0 | — |